



The Strategy of Development of Highly Specific Antiviral Therapeutics

Guest Editors:

Prof. Dr. Tatiana B. Tennikova

Institute of Chemistry, Saint
Petersburg State University,
199034 Saint Petersburg, Russia

Dr. Vladimir V. Sharoyko

1. Department of Biomedicinal
Chemistry, Institute of Chemistry,
Saint Petersburg State University,
199034 Saint Petersburg, Russia
2. Department of General and
Bioorganic Chemistry, First
Pavlov Saint Petersburg State
Medical University, 199034 Saint
Petersburg, Russia

Deadline for manuscript
submissions:

closed (20 December 2021)

Message from the Guest Editors

Dear Colleagues,

The emergence of viral diseases is expected to accelerate in recent years. These data dictate the need for active approaches to the development of widely active family-specific and cross-family therapies for use in future disease outbreaks. Advances in this area have been achieved through efforts and technical discoveries in various fields of science. The focus should be not only on the development of broad-spectrum, low-molecular-weight antivirals and direct-acting antibodies, but also on therapeutics associated with host factors, including the repurposing of previously approved or under development drugs. This Special Issue aims at the strategy of the development of highly specific antiviral therapeutics based on anti- and nanobodies, RNA, DNA, and peptide aptamers, siRNA, anti-sense oligos, and small organic molecules. *Pharmaceutics* is open to both original research articles and review articles focusing on the strategy of development of highly specific antiviral therapeutics. We look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma